Back to Search
Start Over
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.
- Source :
-
Science Advances . 7/22/2022, Vol. 8 Issue 29, p1-19. 19p. - Publication Year :
- 2022
-
Abstract
- The article presents a study on a therapeutic KRASG12C (glycine 12 to cysteine) inhibitor that drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. It discusses that the in vivo KRASG12C inhibitor increases the T cell infiltration and activation. It also describes the mechanism of the KRASG12C inhibition reverses immunosuppression in several preclinical lung cancer models with varying levels of immunogenicity.
Details
- Language :
- English
- ISSN :
- 23752548
- Volume :
- 8
- Issue :
- 29
- Database :
- Academic Search Index
- Journal :
- Science Advances
- Publication Type :
- Academic Journal
- Accession number :
- 158134945
- Full Text :
- https://doi.org/10.1126/sciadv.abm8780